SCHEMBL15529296

SCHEMBL15529296

O=C(Nc1ccc(CC2CCN(C(=O)c3ccccc3)CC2)cc1)N1CC(c2cccnn2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
NAMPT P43490 3/20 0.48
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
NPC1 O15118 1/20 0.46
STAT1 P42224 1/20 0.46
RAB9A P51151 1/20 0.46
GAA P10253 1/20 0.44
HTT P42858 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
GRIN2D O15399 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15529360 0.89 FAAH (0.53) FAAHSMN1; SMN2KMT2AMEN1MAPT
SCHEMBL15528752 0.88 CYP2C9 (0.56) FAAHSMN1; SMN2KMT2AMEN1NAMPT
SCHEMBL15528730 0.87 NAMPT (0.64) SMN1; SMN2NAMPTMAPTNPC1STAT1
SCHEMBL15529459 0.85 FAAH (0.49) FAAHSMN1; SMN2KMT2AMEN1NAMPT
SCHEMBL15529367 0.85 FAAH (0.49) FAAHSMN1; SMN2KMT2AMEN1NAMPT
SCHEMBL15529371 0.85 FAAH (0.48) FAAHSMN1; SMN2KMT2AMEN1NAMPT
SCHEMBL15529226 0.84 FAAH (0.48) FAAHSMN1; SMN2KMT2AMEN1NAMPT
SCHEMBL15529071 0.84 FAAH (0.48) FAAHSMN1; SMN2KMT2AMEN1NAMPT
SCHEMBL15529152 0.84 FAAH (0.45) FAAHSMN1; SMN2KMT2AMEN1NAMPT
SCHEMBL15529563 0.83 FAAH (0.47) FAAHSMN1; SMN2KMT2AMEN1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296723-B2 NAMPT inhibitors ABBVIE INC. (US) 2016-03-29 US claimed
EP-2852585-A1 NAMPT INHIBITORS AbbVie Inc. (US) 2015-04-01 EP claimed
US-20140336168-A1 NAMPT INHIBITORS ABBVIE INC. 2014-11-13 US claimed
WO-2013170113-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 WO claimed
US-9758511-B2 NAMPT inhibitors ABBVIE INC. (US) 2017-09-12 US disclosed
US-20160168134-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2016-06-16 US disclosed
US-9296723-B2 NAMPT inhibitors ABBVIE INC. (US) 2016-03-29 US disclosed
EP-2852585-A1 NAMPT INHIBITORS AbbVie Inc. (US) 2015-04-01 EP disclosed
US-20140336168-A1 NAMPT INHIBITORS ABBVIE INC. 2014-11-13 US disclosed
WO-2013170113-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168134-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FAAH 3211/4885SMN1; SMN2 334/4885KMT2A 2175/4885
US-20140336168-A1 NAMPT INHIBITORS NAMPT, NNMT, NAPRT FAAH 3211/4885SMN1; SMN2 334/4885KMT2A 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.